Good to see ya again.
Please let Joe F he's welcome here
Good to see ya again.
Please let Joe F he's welcome here and on the Todos board anytime.
As for that other guy, he's been known as an assclown for a years, but in fact he's a vile POS racist and deranged pathological liar who wants to harm everyone's investment.
I know what I'd do if someone wanted to steal money and take food out of my baby's mouth and from my family.
I thought he was an unemployed washed up drunk...
How he has a job is beyond me. I hear his job may be in jeopardy after they find out he spends his time spewing racist bigoted remarks all day long while on the Gov't dime.
He might want to cool it. I understand it's going to probably get real bad for him if he keeps it up.
As goes Todos, so goes AMBS !
Things look to be coming together quickly now.
Looking forward to Superbowl weekend and all the news coming out from now till then.
2
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
SmartFinancial Announces Upcoming Earnings Release SmartFinancial, Inc. (NYSE: SMBK) has revealed important details regarding its Fourth Quarter earnings for the year 2024. This is an exciting time for investors and stakeholders as the company prepares to share insights into its financial performance. Earnings Release Date and Conference Call Information The earnings...
Continue Reading
IntouchCX Strengthens Trust and Safety Solutions Through Acquisition IntouchCX has recently made headlines with its acquisition of WebPurify, a leading provider of innovative content moderation solutions that harness the power of artificial intelligence. This strategic move represents a significant advancement in IntouchCX's mission to redefine Trust and Safety solutions,...
Continue Reading
Y-mAbs Therapeutics Engages Investors at Upcoming Conferences This September, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a key player in the biopharmaceutical industry, is poised to attract investor interest. The company is known for its innovative radioimmunotherapy and antibody-based treatments designed to transform cancer care. Michael Rossi, the energetic CEO of...
Continue Reading
Overview of CorVel's Financial Performance CorVel Corporation (NASDAQ: CRVL) recently unveiled impressive results for the quarter and fiscal year, showcasing strong revenue gains and enhanced earnings metrics. The quarterly revenue hit $232 million, a notable rise from $207 million compared to the same quarter last year. This upward trend is mirrored across the fiscal...
Continue Reading
IQAX eBL Interoperability Approval Highlights IQAX Limited has made significant strides in enhancing its electronic bill of lading (eBL) solution by receiving official approval from the International Group of P&I Clubs (IG P&I Clubs). This approval affirms the capabilities of IQAX eBL's interoperable addendum, empowering users to perform eBL transactions across different...
Continue Reading